Quick Summary:
Navigate the evolving Non-Infectious Macular Edema Treatment market with our comprehensive research report. Forecasted to expand from US$14.5 billion in 2022 to a remarkable US$22.4 billion by 2030, this market offers multifaceted opportunities for growth and expansion. From detailed breakdowns of market segmentation to an insightful analysis on the rise of Anti-VEGF therapies, this report is a vital tool for senior executives seeking to strategize and capitalize on the upsurges in this industry.
Shedding light on anticipated growth rates from leading markets including the U.S. and China to emerging spaces such as Japan and Germany, the report transcends borders, equipping you for success in the global arena. Alongside geopolitical insights, it includes a competitive analysis of active players and their market shares. Featuring access to digital archives and providing complimentary annual updates, our report is an integral asset for staying ahead in the bustling Non-Infectious Macular Edema Treatment market.
Global Non-Infectious Macular Edema Treatment Market to Reach $22.4 Billion by 2030
The global market for Non-Infectious Macular Edema Treatment estimated at US$14.5 Billion in the year 2022, is projected to reach a revised size of US$22.4 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2022-2030. Anti-VEGF, one of the segments analyzed in the report, is projected to record 5.3% CAGR and reach US$14.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Corticosteroids segment is readjusted to a revised 6.7% CAGR for the next 8-year period.
The U.S. Market is Estimated at $4.3 Billion, While China is Forecast to Grow at 5.2% CAGR
The Non-Infectious Macular Edema Treatment market in the U.S. is estimated at US$4.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$3.9 Billion by the year 2030 trailing a CAGR of 5.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 4.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.Select Competitors (Total 46 Featured) -
- AbbVie, Inc.
- Alimera Sciences, Inc.
- Allergan PLC
- Amgen, Inc.
- Bausch Health Companies, Inc.
- Bayer AG
- Clearside Biomedical, Inc.
- F. Hoffmann-La Roche AG
- Novartis International AG
- Pfizer, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Non-Infectious Macular Edema Treatment?
What is the growth rate of the Global Market for Non-Infectious Macular Edema Treatment?
What is the forecasted size of the Global Market for Non-Infectious Macular Edema Treatment?
Who are the key companies in the Global Market for Non-Infectious Macular Edema Treatment?
| Report Attribute | Details |
|---|---|
| No. of Pages | 196 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 14.5 Billion |
| Forecasted Market Value ( USD | $ 22.4 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbbVie, Inc.
- Alimera Sciences, Inc.
- Allergan PLC
- Amgen, Inc.
- Bausch Health Companies, Inc.
- Bayer AG
- Clearside Biomedical, Inc.
- F. Hoffmann-La Roche AG
- Novartis International AG
- Pfizer, Inc.
